Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 13/20 | 0.71 |
| ▸ | STK3 | Q13188 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514941 | 1.00 | STK4 (0.71) | STK4STK3EGFRERBB2 | |
| SCHEMBL5255823 | 0.96 | STK4 (0.65) | STK4STK3EGFRERBB2 | |
| SCHEMBL13915763 | 0.89 | STK4 (0.59) | STK4STK3EGFRERBB2 | |
| SCHEMBL2131485 | 0.88 | STK4 (0.57) | STK4STK3EGFRERBB2 | |
| SCHEMBL30847382 | 0.88 | STK4 (0.68) | STK4STK3EGFRERBB2 | |
| SCHEMBL2543431 | 0.88 | STK4 (0.68) | STK4STK3EGFRERBB2 | |
| SCHEMBL14048142 | 0.88 | STK4 (0.70) | STK4STK3EGFRERBB2 | |
| SCHEMBL5261113 | 0.84 | STK4 (0.55) | STK4EGFRERBB2 | |
| SCHEMBL29515043 | 0.83 | STK4 (1.00) | STK4STK3EGFRERBB2 | |
| SCHEMBL22419865 | 0.83 | STK4 (1.00) | STK4STK3EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679473-B | Lenatinib intermediate crystal, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-114605321-A | Impurities of substituted butene amide raw material and preparation product and analysis method thereof | 苏中药业集团股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-112679473-A | Lenalitinib intermediate crystal, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-111875539-A | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 江苏苏中药业集团股份有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-112679473-B | Lenatinib intermediate crystal, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| CN-114920695-B | Quinazoline derivative, preparation method thereof, pharmaceutical composition and application | 深圳大学总医院 | 2023-06-20 | — | — | CN | disclosed |
| WO-2006127207-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1711467-A2 | QUINOLINE INTERMEDIATES OF RECEPTOR TYROSINE KINASE INHIBITORS AND THE SYNTHESIS THEREOF | Wyeth (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005070890-A2 | QUINOLINE INTERMEDIATES OF RECEPTOR TYROSINE KINASE INHIBITORS AND THE SYNTHESIS THEREOF | WYETH (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050159446-A1 | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | WYETH | 2005-07-21 | — | — | US | disclosed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | STK4 162/4885STK3 86/4885EGFR 2/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | STK4 168/4885STK3 138/4885EGFR 6/4885 |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | STK4 64/4885STK3 25/4885EGFR 6/4885 |
| US-20050159446-A1 | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | ABL1, RET, ERBB2 | STK4 318/4885STK3 532/4885EGFR 8/4885 |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | STK4 997/4885STK3 856/4885EGFR 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.